Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vision loss
Biotech
Atsena gene therapy hits safety goals, closes retinal splits
Gene therapy outfit Atsena Therapeutics has debuted data showing its eye disease candidate led to no serious treatment-related adverse events.
Darren Incorvaia
May 19, 2025 12:59pm
MeiraGTx gene therapy allows 11 blind children to see
Feb 21, 2025 10:50am
Gene editing biotech Graphite merges into vision loss biotech
Nov 15, 2023 9:57am
Astellas inks $6B Iveric buyout ahead of FDA eye disease ruling
May 1, 2023 8:13am
J&J links gene therapy to improved vision in early-phase trial
Oct 3, 2022 8:00am
Dry AMD developer LumiThera nets retina diagnostic maker Diopsys
Mar 4, 2022 10:40am
